Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience -- Ignore unavailable to you. Want to Upgrade?

To: Green Receipt who wrote (516)	6/24/1999 9:12:00 PM
From: Mike McFarland	Respond to of 675

CNSI stock has been fairly steady around a buck since the annual meeting, which should have been on 6/3/99 according to my proxy. So, apparently there was nothing to interesting brought up at the meeting...or maybe nobody showed? And we have not heard anything from the company since the last quarterly report, fine, these things take time. But it seems like this may be about the time we hear about those IND's yes? Also, CNSI had an exhibit at that informed investors thing--anybody go, anybody see the display? Seems like such a long list for things to be so quiet, doesn't it? I really should forget I own this one and just come back in five years. recap.com

To: Green Receipt who wrote (516)	7/23/1999 10:13:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 675

Second Quarter 1999 Financial Results biz.yahoo.com (snip) The increase in revenue was attributable to research reimbursements by Bayer AG of costs incurred by the Company under its GGF collaboration. The Company's cash balance as of June 30, 1999 was $10.8 million, a decrease of $1.1 million since December 31, 1998. ''By continuing to focus resources on our two externally-funded programs, we have been able to effectively manage expenditures,'' said Harry Wilcox, Chief Executive Officer of the Company. ''We continue to be pleased with the progress of our collaborations with Allergan for ophthalmic disorders and Bayer for multiple sclerosis and other neuropathies.'' ____ lean and mean, cnsi is a damn good value-- ...it may be several more years however David-- just be ready to do a quick trade if they file INDs and something gets out into the press about it.